EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities

Hannah D McManus, Daniel J George, Jeffrey W Shevach

Journal of the National Comprehensive Cancer Network · 2026-07 · 24 (7)

DOI: 10.6004/jnccn.2026.7002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-07. Verfasst von Hannah D McManus und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medicine, Duke University School of Medicine, Durham, NC. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Clinical Trials as Topic, Patient Selection. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) care has undergone a significant transformation in the past decade, leading to unprecedented survival outcomes, particularly for patients with newly diagnosed metastatic disease. However, there is a sizable gap in efficacy and toxicity between PC clinical trial populations and those in the real world. Additionally, there has been a persistent lack of adoption of modern PC therapies, particularly in the metastatic hormone-sensitive PC setting. A key reason for slow adoption, despite robust survival data, is that clinicians feel that their patients are not adequately reflected in clinical trial populations. Key populations that have been underrepresented in PC trials include older adults, individuals with comorbidities, rural populations, and people of non-European ancestry. The lack of these patient populations in modern PC clinical trials impacts the broader adoption of modern therapies, limits our understanding of real-world effectiveness and adverse effect profiles, and hinders the discovery of ancestry-related clinical or pharmacogenomic biomarkers. In this review, we propose multiple strategies to help shape clinical trial populations to better reflect the patients we see in the real world, particularly in later-phase studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsClinical Trials as TopicPatient SelectionHumansMale

Autor:innen und Institutionen

  • 1Department of Medicine, Duke University School of Medicine, Durham, NC.
  • 2Duke Cancer Institute, Center for Prostate and Urologic Cancers, Durham, NC.

Zitieren

APA

McManus, H. D., George, D. J., & Shevach, J. W. (2026). Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities. Journal of the National Comprehensive Cancer Network, 24(7). https://doi.org/10.6004/jnccn.2026.7002

Vancouver

McManus HD, George DJ, Shevach JW. Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities. Journal of the National Comprehensive Cancer Network. 2026;24(7). doi:10.6004/jnccn.2026.7002

BibTeX
@article{McManus2026,
  author = {McManus, Hannah D and George, Daniel J and Shevach, Jeffrey W},
  title = {Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {7},
  doi = {10.6004/jnccn.2026.7002}
}
Kostenlos starten →